The US Food and Drug Administration (FDA) is taking a significant step by removing the lengthy "black box" warning from hormone treatments for menopause symptoms. This decision is expected to empower women with more treatment options and lead to a surge in new prescriptions. Hormone therapy has been available for a long time, but its prescriptions plummeted after 2003 due to a warning about increased risks of cardiovascular disease, stroke, breast cancer, and dementia. However, prescribing hormones requires careful consideration, as some women still face risks, including those at increased risk of blood clots or with a history of breast cancer. FDA officials emphasize the need for nuance in prescribing, suggesting that hormones should be used in women under 60 or within 10 years of menopause. The black box warning, the strongest alert the FDA can issue, has been a significant barrier to this life-changing and sometimes life-saving treatment. It was added after a study found that women taking estrogen pills post-menopause had higher health risks. Since the study and label change, doctors have been hesitant to prescribe hormone therapy, leading to a dramatic drop in prescriptions. This has resulted in undertreatment of symptoms that can be debilitating for women in midlife. Experts, including Dr. Erika Schwartz, argue that hormone therapy is crucial for managing symptoms like hot flashes and mood swings. Recent analyses of the Women's Health Initiative suggest that hormone therapy started in women under 60 or within 10 years of menopause can safely help manage menopausal symptoms, provided there are no specific contraindications. The menopause medical community has long advocated for the removal of the black box warning, and the FDA's action aligns with a wave of policies introduced across the country to improve menopause care. This move will make hormone therapy, especially estrogen, more accessible for midlife women, addressing the need for equitable and accessible treatments.
